Goodwin Procter advised Wave Life Sciences on the deal. Wave Life Sciences (Nasdaq: WVE) announced its strategic collaboration with GSK (LSE/NYSE: GSK) to advance oligonucleotide therapeutics, including...
You must be a Standard 1 Year member to access this content.
Cleary Gottlieb represented Takeda in the transaction while Goodwin Procter advised Nimbus Therapeutics. Takeda (TSE:4502/NYSE:TAK) announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Jnana Therapeutics on the deal. Jnana Therapeutics announced its second collaboration and license agreement with Roche for the discovery of small molecule drugs for...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Nimbus Therapeutics on the deal. Nimbus Therapeutics announced its Research Collaboration and License Agreement with Eli Lilly and Company for the exclusive and worldwide...
You must be a Standard 1 Year member to access this content.
Johnson Winter & Slattery worked with Moderna’s US lawyers, Goodwin Procter LLP on the matter. Moderna, a pioneer in mRNA vaccines, signed a 10-year strategic deal with...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Minovia Therapeutics on the deal. Minovia Therapeutics announced its worldwide strategic collaboration and license agreement with Astellas Pharma (TSE: 4503) to research, develop, and...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Schrödinger on the deal. Schrödinger (Nasdaq: SDGR) announced its global discovery, development and commercialization collaboration with Zai Lab Limited focused on a novel program...
You must be a Standard 1 Year member to access this content.
